Abstract

Systems biology offers promising approaches for identifying response-specific signatures to vaccination and assessing their predictive value. Here, we designed a modelling strategy aiming to predict the quality of late T-cell responses after vaccination from early transcriptome analysis of dendritic cells. Using standardized staining with tetramer, we first quantified antigen-specific T-cell expansion 5 to 10 days after vaccination with one of a set of 41 different vaccine vectors all expressing the same antigen. Hierarchical clustering of the responses defined sets of high and low T cell response inducers. We then compared these responses with the transcriptome of splenic dendritic cells obtained 6 hours after vaccination with the same vectors and produced a random forest model capable of predicting the quality of the later antigen-specific T-cell expansion. The model also successfully predicted vector classification as low or strong T-cell response inducers of a novel set of vaccine vectors, based on the early transcriptome results obtained from spleen dendritic cells, whole spleen and even peripheral blood mononuclear cells. Finally, our model developed with mouse datasets also accurately predicted vaccine efficacy from literature-mined human datasets.

Highlights

  • The development of vaccines against complex chronic diseases such as HIV or cancer has been largely unsuccessful so far

  • The various vector platforms used in vaccine development are diverse and complex, rendering the selection of promising vaccines vector challenging

  • The forty-one vectors included (i) recombinant viral vectors derived from adenovirus, vaccinia (VACC), modified vaccinia Ankara (MVA) and lentivirus (LV), (ii) recombinant bacteria vectors derived from Bacille de Calmette et Guérin (BCG), (iii) recombinant virus-like particles (VLPs) made of the AP205 [10] or Qbeta (Qb) [11] proteins from bacteriophage, the VP2 proteins from murine polyoma virus (MPY) [12] or murine pneumotropic virus (MPT), the Gag capsid proteins from murine leukaemia virus (MLV) [13], the core from hepatitis B virus (HBc), and (iv) plasmid encoding a recombinant protein (DNA) or recombinant MLV-VLPs [13,14]

Read more

Summary

Introduction

The development of vaccines against complex chronic diseases such as HIV or cancer has been largely unsuccessful so far. Novel vaccine technologies are rationally designed to generate appropriate protective immune responses [1], notably efficient T-cell responses. Such vaccine vectors include plasmid DNA, viral and bacterial vectors, and virus-like particles (VLPs). The intrinsic characteristics of these vectors, including their capacity to stimulate innate immunity and to activate and target the antigen to antigen-presenting cells, determine in large part their immunogenicity and their potency as vaccine or gene therapy vectors [2,3,4]. Multivariate analysis performed on human peripheral blood mononuclear cell (PBMC) microarray data, obtained 3 days after vaccination, identified innate immune response–related signatures that predicted the late adaptive immune response to the YF-17D yellow fever vaccine [9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call